Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... such as decitabine (5-aza-2'-deoxycytidine) and azacitidine (5-azacytidine), have been approved during the past decade and ...

    Research Article last updated 11/05/2012 - 9:34am.

  2. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    ... in MDS. The two hypomethylating agents, 5-azacytidine ( azacitidine ) and 5-aza-2-deoxycytidine ( decitabine ), are both ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine

    ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.

    ... gene. The trend of methylation in patients treated with azacitidine was analyzed in CDKN2B gene and correlated with the course of ...

    Research Article last updated 04/26/2012 - 8:35am.

  5. MDS Drug Therapy

    ... (FDA) has approved three medicines to treat MDS: Azacitidine (Vidaza®) for both low- and high-risk patients with all ... Azacitidine (Vidaza®) Azacitidine ...

    Topic section last updated 03/10/2016 - 11:26pm.

  6. Lousiville Community Connection Support Group

    ...

    Group last updated 03/24/2017 - 12:51pm.

  7. Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

    ... Must be ≥ 18 yrs old and ≤ 70 yrs old. Azacitidine is not approved by the FDA for use in children. Must have ... any related procedures being performed. The effects of azacitidine on the developing human fetus at the recommended therapeutic dose ...

    Clinical Trial last updated 05/02/2016 - 2:07pm.

  8. Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

    ... The purpose of this study is to learn if 5'- Azacitidine will help to lower the risk of the disease coming back after a ... also be looking at the side effects of this medicine. 5'-Azacitidine is an FDA approved drug for treatment of MDS and AML, as well as ...

    Clinical Trial last updated 04/27/2016 - 1:19pm.

  9. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard dosing schedule, may ... Associated Drug(s):  Azacitidine Decitabine Phase:  ...

    Clinical Trial last updated 04/28/2016 - 10:22am.

  10. Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

    ... kills unhealthy cells in bone marrow . Vidaza® ( azacitidine ), a hypomethylating agent, is the current standard treatment for high-risk MDS. Azacitidine is typically injected under the skin (subcutaneously) or into a ...

    Research Review last updated 05/02/2016 - 9:27am.